Item 2.02 - Results of Operations and Financial Condition: The filing reports Humana Inc.'s financial results and operational performance as of July 29, 2026 Item 7.01 - Regulation FD Disclosure: The company is making additional disclosures under Regulation Fair Disclosure, indicating material information is being shared with investors Item 9.01 - Financial Statements and Exhibits: The filing…

Our analysis rates this filing NEUTRAL. This filing presents a routine earnings disclosure with expected non-GAAP adjustments rather than material operational deterioration. The 22% GAAP guidance reduction is fully explained by identifiable non-cash items ($219M in Q2 charges) rather than…

Concern level: MODERATE (3.5/10). Key factors: GAAP EPS guidance reduced 22% (from $8.36 to $6.52 for FY2026) - material near-term earnings headwind; Non-cash charges totaling $219M in Q2 ($8M amortization + $211M put/call valuation adjustments) creating earnings volatility; Overall risk trend remains STABLE with no new high-severity risks identified.

Notable risk changes: GAAP EPS guidance revised downward from 'at least $8.36' to 'at least $6.52' for FY2026 - 22% reduction in GAAP guidance; Affirmed Adjusted EPS guidance of 'at least $9.00' and Insurance segment benefit ratio guidance of 92.75% ±25bps, indicating management confidence in core operations despite GAAP headwind; Continued strategic expansion with Illinois Medicaid statewide contract award (new…

The model predicts HUM will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.